MedPath

The comparison of hydroquinone and Melfade in the treatment of melasma

Phase 2
Conditions
melasma.
Chloasma
Registration Number
IRCT138809212840N1
Lead Sponsor
Kurdistan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
62
Inclusion Criteria

woman with physician diagnosed melasma.
Exclusion criteria: history of the consumption of steroid, Melfade and hydroqinone drugs in recent 30 days, pregnancy, lactation, present history of OCP drug consumption.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Faint-colored of scar. Timepoint: 12 weeks. Method of measurement: observation.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath